Michael David  Garrison net worth and biography

Michael Garrison Biography and Net Worth

Dr. Michael Garrison serves as executive vice president and president of the Medical Segment of BD (Becton, Dickinson and Company), a leading global medical technology company headquartered in Franklin Lakes, New Jersey. In this role, he is responsible for driving the global operational, commercial and financial performance of the three business units that comprise BD’s largest segment, including BD Medication Delivery Solutions, BD Medication Management Solutions and BD Pharmaceutical Systems. He is also a member of the BD Executive Leadership Team.

Dr. Garrison most recently served as worldwide president of BD Medication Management Solutions. In this role, he advanced BD 2025 priorities and drove growth through next-generation solutions supporting BD’s commitment to Smart, Connected Care and New Care Settings. He also led the team responsible for advancing BD’s 510(k) submission for Alaris. Additionally, he oversaw several successful tuck-in M&A deals, including the recent acquisition of Parata Systems – BD’s largest acquisition since Bard in 2017.

Since joining BD in 2005, Dr. Garrison has led teams with deep industry knowledge, operational excellence and a global view. He has a track record of building high-performing teams, applying a customer perspective to his work and driving growth. He previously served as worldwide president of the BD Surgery business unit, vice president and general manager of Infusion Systems, vice president of Research and Development (R&D) for BD Medication Delivery Solutions and Greater Asia and other earlier roles in R&D and platform leadership.

Dr. Garrison earned a Ph.D. in Bioengineering from the University of Washington and Bachelor and Master of Science degrees in Biomedical and Electrical Engineering from Duke University. He is an associate adjunct professor of Bioengineering at the University of Washington and a member of the University of Washington Department of Bioengineering Industrial Advisory Board and the Advisory Board of the Center for Dialysis Innovation.

Dr. Garrison is also a member of the Board of Governors for Biocom California, the association representing the California life sciences industry. He is a living kidney donor to his father, David.

What is Michael David Garrison's net worth?

The estimated net worth of Michael David Garrison is at least $1.25 million as of April 30th, 2024. Dr. Garrison owns 5,381 shares of Becton, Dickinson and Company stock worth more than $1,246,993 as of July 19th. This net worth evaluation does not reflect any other assets that Dr. Garrison may own. Additionally, Dr. Garrison receives an annual salary of $1,730,000.00 as EVP at Becton, Dickinson and Company. Learn More about Michael David Garrison's net worth.

How old is Michael David Garrison?

Dr. Garrison is currently 54 years old. There are 6 older executives and no younger executives at Becton, Dickinson and Company. The oldest executive at Becton, Dickinson and Company is Mr. David B. Hickey, Executive VP & President of Life Sciences Segment, who is 60 years old. Learn More on Michael David Garrison's age.

What is Michael David Garrison's salary?

As the EVP of Becton, Dickinson and Company, Dr. Garrison earns $1,730,000.00 per year. There are 2 executives that earn more than Dr. Garrison. The highest earning executive at Becton, Dickinson and Company is Mr. Thomas E. Polen Jr., President, CEO & Chairman, who commands a salary of $3,460,000.00 per year. Learn More on Michael David Garrison's salary.

How do I contact Michael David Garrison?

The corporate mailing address for Dr. Garrison and other Becton, Dickinson and Company executives is 1 BECTON DRIVE, FRANKLIN LAKES NJ, 07417. Becton, Dickinson and Company can also be reached via phone at (201) 847-6800 and via email at [email protected]. Learn More on Michael David Garrison's contact information.

Has Michael David Garrison been buying or selling shares of Becton, Dickinson and Company?

Michael David Garrison has not been actively trading shares of Becton, Dickinson and Company during the past quarter. Most recently, Michael David Garrison sold 1,715 shares of the business's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a transaction totalling $399,269.15. Following the completion of the sale, the executive vice president now directly owns 5,381 shares of the company's stock, valued at $1,252,750.61. Learn More on Michael David Garrison's trading history.

Who are Becton, Dickinson and Company's active insiders?

Becton, Dickinson and Company's insider roster includes Simon Campion (EVP), Alexandre Conroy (EVP), Christopher DelOrefice (Exec. VP & CFO ), Claire Fraser (Director), John Gallagher (VP), Michael Garrison (EVP), Roland Goette (EVP), David Hickey (EVP), Patrick Kaltenbach (EVP), Samrat Khichi (EVP), Betty Larson (EVP), James Lim (EVP), Thomas Polen, Jr. (Insider), Rebecca Rimel (Director), and Thomas Spoerel (VP). Learn More on Becton, Dickinson and Company's active insiders.

Are insiders buying or selling shares of Becton, Dickinson and Company?

During the last year, insiders at the medical instruments supplier sold shares 10 times. They sold a total of 16,634 shares worth more than $4,166,149.15. The most recent insider tranaction occured on June, 10th when SVP Thomas J Spoerel sold 300 shares worth more than $71,793.00. Insiders at Becton, Dickinson and Company own 0.3% of the company. Learn More about insider trades at Becton, Dickinson and Company.

Information on this page was last updated on 6/10/2024.

Michael David Garrison Insider Trading History at Becton, Dickinson and Company

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/30/2024Sell1,715$232.81$399,269.155,381View SEC Filing Icon  
8/8/2023Sell1,300$277.13$360,269.005,157View SEC Filing Icon  
See Full Table

Michael David Garrison Buying and Selling Activity at Becton, Dickinson and Company

This chart shows Michael David Garrison's buying and selling at Becton, Dickinson and Company by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Becton, Dickinson and Company Company Overview

Becton, Dickinson and Company logo
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
Read More

Today's Range

Now: $231.74
Low: $231.49
High: $235.55

50 Day Range

MA: $232.52
Low: $221.47
High: $240.63

2 Week Range

Now: $231.74
Low: $218.75
High: $287.32

Volume

1,057,971 shs

Average Volume

1,433,698 shs

Market Capitalization

$66.98 billion

P/E Ratio

51.04

Dividend Yield

1.65%

Beta

0.42